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Humans are the natural hosts for JC virus (JCV) 
and BK virus (BKV), two viruses classified within the 
Poliomaviridae family. The viruses are usually non-
pathogenic for non-immunocompromised individuals, 
but reactivation in immunocompromised patients with 
cellular immunodeficiency has been associated with se-
rious complications. Transmission is thought to occur 
through the respiratory route and perhaps by the faecal-
oral route (Weimberg & Mian 2010).
The most common site of BKV latency in humans is 
the urogenital tract and viral sequences can be detected in 
up to 50% of human kidneys. Peripheral blood mononu-
clear cells (PBMC) are a second important site of BKV la-
tency. Compared to healthy subjects, there is an increased 
incidence of viruria in human immunodeficiency virus 
(HIV)-infected individuals, ranging from 20-44% in most 
studies (Markowitz et al. 1993, Sundsfjord et al. 1994, De-
gener et al. 1997, Behzad-Behbahani et al. 2004).
JCV is neurotropic and reactivation of its latent infec-
tion causes progressive multifocal leukoencephalopathy 
(PML), a fatal demyelinating neurological disease, in 
immunocompromised individuals. Reactivation of hu-
man polyomavirus may also occur in otherwise healthy 
people, leading to asymptomatic viruria (Major & Ault 
1995). Many questions concerning the pathogenesis and 
natural history of BKV and JCV infection remain unan-
swered, especially in children and adolescents exposed to 
HIV-infection. The objectives of this observational study 
were: (i) characterise JCV and BKV viruria in a group of 
HIV-1-infected children and adolescents and in a group of 
healthy controls and (ii) describe clinical and laboratory 
parameters of the HIV-infected subjects that were positive 
for BKV and/or JCV viruria during the study period.
PATIENTS, MATERIALS AND METHODS
Study subjects and samples - One hundred and fif-
ty-six subjects were enrolled in this study from March 
2007-April 2008. The subjects were divided into two 
groups. The first group (Group I) included 116 HIV-in-
fected children and adolescents followed at the Paediatric 
AIDS Outpatient Clinic of the Federal University of São 
Paulo (UnIFeSP), Brazil. The second group (Group II) 
included 40 non-HIV-infected healthy controls selected 
by age in a public elementary school after the parents 
provided a signature of informed consent. The stage of 
immunodeficiency in the HIV infected individuals was 
defined according to the CDC Classification (1994). 
Clinical characteristics of Group I are shown in Table I.
The protocol was approved by the ethical Committee 
of the UnIFeSP and all parents gave written informed 
consent prior to their child’s enrolment in the study. Af-
ter obtaining informed consent, a urine sample from 
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The aim of this study was to characterize the urinary excretion of the BK (BKV) and JC (JCV) human polyomavi-
ruses in a cohort of human immunodeficiency virus (HIV)-infected children and adolescents. One hundred and fifty-
six patients were enrolled: Group I included 116 HIV-infected children and adolescents [median age = 11.4 years (y); 
range 1-22 y]; Group II included 40 non-HIV-infected healthy controls (median age = 11.37 y; range 7-16 y). Single 
urine samples from both groups were screened for the presence of JCV and BKV DNA by polymerase chain reaction 
at enrolment. The overall rate of JCV and BKV urinary excretion was found to be 24.4% and 40.4%, respectively 
(n = 156). Group I had urinary excretion of JCV and BKV in 27.6% and 54.3% of subjects, respectively. In contrast, 
Group II showed positive results for JCV in 17.5% of subjects and for BKV in 12.5% of subjects (p Pearson JCV = 
0.20; p Pearson BKV < 0.0001). In Group I, there was no association between JCV/BKV shedding and age, gender 
or CD4 values. Patients with an HIV viral load < 50 copies/mL had a lower excretion of BKV (p < 0.001) and a trend 
of lower JCV excretion (p = 0.07). One patient in Group I (1/116, 0.9%) showed clinical and radiological features 
consistent with progressive multifocal leukoencephalopathy, suggesting that children with HIV/polyomavirus coin-
fection should be kept under surveillance.
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each patient was screened using a standard polymerase 
chain reaction (PCR) technique for the presence of JCV 
and BKV DnA at enrolment. Samples were sent to the 
Laboratory of Virology, Institute of Tropical Medicine, 
São Paulo, Brazil and stored at -70ºC until processing.
Detection of JCV and BKV DNA in urine samples - 
JCV and BKV DnA was extracted from 200 µL of urine 
samples by resin columns (QIAmp® DnA Blood Mini 
Kit, Qiagen, Germany) according to the manufacturer’s 
instructions. The algorithm explaining the strategy used 
for the identification of positive samples for both human 
polyomavirus BK and JC is shown in Figure. 
DnA amplification of a region common to both JCV 
and BKV was used for screening. Amplification was 
performed using standard PCR technique in a Perkin 
elmer 2400 or PTC 100 thermocycler. The set of prim-
ers PeP-1 and PeP-2, which were described by Arthur 
et al. (1999) (5’-AGTCTTTAGGGTCTTCTACC-3’, 5’-
GGTGCCAACCTATGGAACAG-3’) and amplify the T-
antigen genes (173 bp) of both JCV and BKV, was used. 
The PCR mixture (50 μL) contained 10 μL of extracted 
DnA, deoxynucleotide triphosphates at a concentration 
of 200 μM each, 0.5 μM of primers, 1 × reaction buffer 
(10 mM Tris, 50 mM KCl, pH 8.3), 1.5 mM MgCl2 and 
Taq (2.5 U/reaction). The target DnA was amplified us-
ing 40 thermal cycles (92ºC for 1.5 min, 55ºC for 1.5 min, 
72ºC for 2 min, with a final elongation step of 7 min). 
Samples that were positive for T antigen were submitted 
to two extra PCRs to discriminate between the JCV and 
BKV. JCV DnA was detected by amplifying a 215 bp 
fragment of the VP1 gene in a one step PCR reaction 
(nucleotides 1710-1734 and 1924-1902) (Agostini et al. 
1997). The amplification was performed according to 
Shaffer et al. (2006). BKV DnA was detected by am-
plifying a 354 nucleotide region within the VP1 gene 
Algorithm showing the strategy used for the identification of positive 
samples for both human polyomavirus BK and JC. BKV: BK virus; 
JCV: JC virus; PCR: polymerase chain reaction.
Samples
(n = 156)
Screening
PCR AgT
(Arthur et al. 1999)
Negative
samples
(stop)
Positive
samples
(2 extra PCRs)
PCR JCV
(Agostini et al. 1997)
PCR BKV
(Jin et al. 1993)
TABLe I
Characteristics of the study population
Group I
(n = 116)
Group II
(n = 40)
Age in years (mean; range) 11.4; 1-20 12; 7-16
Gender [n (%)]
   Male 63 (54) 30 (75)
   Female 53 (46) 10 (25)
HIV immunologic category [n (%)]
   1 23 (19.8) -
   2 45 (38.8) -
   3 48 (41.4) -
HIV clinical category [n (%)]
   n/A 26 (22.4) -
   B 52 (44.8) -
   C 38 (32.8) -
HIV viral load < 50 (copies/mL) at inclusion [n (%)] 35 (30.2) -
HIV viral load < 400 (copies/mL) at inclusion [n (%)] 60 (51.7) -
HIV viral load after 24 months of follow-up [n (%)]
   < 50 (copies/mL) 44 (38.3) -
   ≤ 10,000 50 (43.5) -
   > 10,000 21 (18.3) -
CD4 nadir (cells/mm3) (mean; range) 385; 4-1288 -
CD4 at inclusion (cells/mm3) (mean; range) 671; 18-2023 -
HIV: human immunodeficiency virus.
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(nt 1663-2016, DUn numbering) using the oligonucle-
otides BKV-1 (50-GAAGTTCTAGAAGTTAAAACT-
GGG-30) and BKV-2 (50-GTGGAAATTACTGCCTT-
GAATAGG-30) (Jin et al. 1993). 
Statistical analyses - Univariate analysis was per-
formed to evaluate the variables significantly associated 
with JCV and BKV shedding in HIV-infected children. 
The following variables were included: age, clinical cat-
egory, immunological category, viral load < 400 copies/
mL and viral load < 50 copies /mL. Comparisons be-
tween groups were performed using the Pearson chi-
square test (χ2) for categorical variables. The level of 
significance was set at p < 0.05 (SPSS version 15.0).
RESULTS
We collected 116 samples from Group I (n = 116) and 
40 samples from Group II (n = 40). The overall rates of 
JCV and BKV urinary excretion were found to be 25% 
and 40.4%, respectively, including all persons enrolled 
in this study (n = 156). 
Group I exhibited urinary excretion of JCV and BKV 
in 27.6% and 54.3% of subjects, respectively. In contrast, 
Group II showed positive urinary results for 17.5% of sub-
jects for JCV (p = 0.20) and for 12.5% of subjects for BKV 
(p < 0.0001). Twelve of the 116 patients included in Group 
I (10.4%) had JCV/BKV coinfection, which was not seen 
in the subjects from Group II. The demographic charac-
teristics and the occurrence of polyomavirus excretion in 
the urine of the study population are shown in Table II.
Although JCV and BKV DnA was more frequently 
detected in HIV-infected subjects than in non-infected 
subjects, univariate analysis did not show any statisti-
cally significant correlation between the frequency of 
JCV or BKV DnA detection and an HIV viral load of 
< 400 copies/mL or the stage of immunodeficiency of the 
HIV-infected group for either immunological (1 vs. 2 or 3) 
or clinical (n or A vs. B or C) categories (Table III).
Patients with HIV viral load below 50 copies/mL 
were unlikely to be shedding BKV (p < 0.001). Statisti-
cal significance was not reached for JCV (p = 0.07). 
Clinical aspects - All control subjects and the majori-
ty of the HIV-infected patients were asymptomatic at the 
time of sampling. During the study period, the patients 
showing BKV or JCV viruria presented the following 
signs and symptoms: hyporeflexia (n = 1/116; 0.86%), 
seizures (n = 1/116; 0.86%), HIV encephalopathy (n = 
1/116; 0.86%) and learning deficit (n = 1/116; 0.86%). 
One patient from Group I presented severe neurologic 
signs and symptoms during the study period. This pa-
TABLe III
Demographic, clinical and laboratory variables according to JC virus (JCV) and BK virus (BKV) serological status 
in human immunodeficiency virus (HIV)-infected patients
Variable JCV+ JCV- p BKV+ BKV- p
Age (years) n (%) n (%) 0.55 n (%) n (%) 0.8
   1-4.99 2 (1.7) 5 (4.3) - 3 (2.6) 4 (3.4) -
   5-9.99 7 (6) 27 (23.3) - 20 (17.2) 14 (12.1) -
   ≥ 10 23 (19.8) 52 (44.8) - 35(30.2) 40 (34.5) -
Clinical category
   n or A 6 18 - 15 9 -
   B or C 26 66 - 43 49 -
   Total 32 84 0.75 58 58 0.36
Immunological category 
   1 6 16 - 9 13 -
   2 or 3 26 68 - 49 45 -
   Total 32 84 0.97 58 58 0.35
HIV viral load (copies/mL)
   < 50 14 22 0.07 11 (9.5) 25 (21.6) 0.007
   < 400 17 43 0.85 30 30 -
   400 < 10,000 8 15 - 10 13 -
   10,000-100,000 7 21 15 13 -
   > 100,000 0 5 0.45 3 2 0.81
TABLe II
Prevalence of BK virus (BKV) and JC virus (JCV) DnA 
in urine samples from human immunodeficiency 
virus-infected and non-infected patients
Group I 
(n = 116)
Group II 
(n = 40)
Urine samples n (%) n (%) p values
JCV positive 32 (27.6) 7 (17.5) 0.20
BKV positive 63 (54.3) 5 (12.5) < 0.001
Coinfection JCV/BKV 12 (10.4) 0 (0) -
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tient showed clinical and radiological features compat-
ible with PML, such as behaviour disorder, aggression, 
balance disturbance with walking difficulties, tremors 
of the extremities and characteristic magnetic resonance 
imaging (MRI) changes. This patient had positive re-
sults for BKV in both their urine and cerebrospinal fluid 
(CSF) samples. There was slow but progressive improve-
ment of the neurological symptoms and recovery of the 
neurologic deficit after a mean time of six months. De-
spite neurological improvement, the patient presented 
nephrotic range proteinuria and chronic renal failure, 
dying 36 months after inclusion in the study.
DISCUSSION
In the present study, 30% of healthy individuals 
(12/40) had detectable JCV or BKV DnA in their urine. 
This excretion rate is similar to that published previously 
by other authors. Behzad-Behbahani et al. (2004) found 
that excretion rates of JC or BK viruria varied from 33-
60% in non-HIV-infected individuals. Matos et al. (2010) 
observed urinary JCV DnA in 33% of healthy individ-
uals, a detection rate significantly lower than that ob-
served for patients infected with HIV, which was 51%.
Increased incidence of polyomavirus viruria is ob-
served in HIV-infected individuals (Lafon et al. 1998, 
Weimberg & Mian 2010). In our study, the frequency of 
BK viruria was significantly higher in HIV-infected pa-
tients in comparison to healthy control subjects (54.3% 
vs. 12.5%, p < 0.0001), which may be explained by the T 
cell immunodeficiency in HIV-infected patients. How-
ever, a significant difference was not observed in JC 
viruria between HIV-infected and control groups (27.6% 
vs. 17.5%, respectively, p = 0.20). Similar results have 
been reported by other studies (Markowitz et al. 1993, 
Behzad-Behbahani et al. 2004).
In a previous study in HIV-positive individuals, JCV 
and BKV sequences were found in 31.6% and 8.1%, re-
spectively, of urine samples, whereas the positive test 
rate was 22.8% for JCV and as high as 51.1% for BKV in 
PBMCs (Sundsfjord et al. 1994).
BKV/JCV co-infection was frequent in Group I 
(10.4%), but was not detected in Group II. Other studies 
also observed that simultaneous shedding of both BKV 
and JCV DnA in urine samples was significantly higher 
in HIV-infected patients (25.5%) than in HIV-negative 
partners (10%) or patients attending a genitourinary 
medicine clinic (1.6%) (Behzad-Behbahani et al. 2004).
Patient age, clinical or immunological category and 
HIV viral load did not show an association with urinary 
JCV or BKV shedding. The only variable significantly 
associated with a decreased frequency of BKV shedding 
in urine was undetectable HIV viral load. Paradoxically, 
the same was not observed for JCV. These data suggest 
that, besides T cell immunodeficiency, other factors that 
are not well understood may cause JCV replication. 
Several studies have shown that in individuals with 
immunodeficiency, reactivation of JCV may occur in 
oligodendrocytes and astrocytes, leading to PML (An-
tinori et al. 2001, Drake et al. 2007). The diagnosis is 
mainly based on clinical data, images of demyelination 
from MRI and brain biopsy data. The involvement of 
HIV-1 secreted products has been proposed as a possible 
mechanism for stimulating JCV replication and facilitat-
ing the spread of this virus to the central nervous system 
(CnS) (Chowdhury et al. 1992, 1993).
In the present study, most of the patients were as-
ymptomatic during polyomavirus shedding. Interesting-
ly, one patient who presented with neurological mani-
festations had polyomavirus (BKV) in their urine and 
CSF and was diagnosed with PML. Although BKV is 
considered a nephrotropic virus and JCV a CnS-tropic 
virus, a few cases of BK CnS disease have been report-
ed (Weimberg & Mian 2010). Although BKV infections 
in the CnS have been reported less frequently than those 
related to JCV (Fink et al. 2006, Vidal et al. 2007), there 
is evidence for BKV occurrence in the CnS of immuno-
compromised hosts. Therefore, in patients with neuro-
logical alterations and preceding or concurrent signs of 
renal involvement with BK viruria, the possibility of BK 
CnS disease should be investigated (Bratt et al. 1999). 
Other patients in this study had signs and symp-
toms that are frequently found in HIV-infected patients 
and could be unrelated to the HIV/JCV or HIV/BKV 
coinfection. The high frequency of urinary polyoma-
virus excretion reflects the possibility of persistent or 
intermittent replication of the viruses. Also, it might be 
explained by the activation of viral replication caused 
by the interaction between HIV and polyomavirus, 
as suggested by the presence of a higher excretion of 
both BKV and JCV in patients with an HIV viral load 
> 50 copies/mL, although only BKV excretion was sta-
tistically significant (p = 0.007).
The time between reactivation in immunocompro-
mised patients and the emergence of PML is not known. 
The presence of positive responses to antiretroviral 
treatment, as evidenced by HIV viral load < 50 copies/
mL in 38.3% of patients and subsequent maintenance of 
an adequate immune status could be decisive for the ap-
pearance or absence of a demyelinating status. 
In this study, although 66.9% of patients had already 
shown moderate or severe immunosuppression in the 
past, there was an improvement in immune status in the 
subjects, as evidenced by an increase in median CD4 
counts when compared to CD4 nadir counts. As many pa-
tients are still presenting HIV replication (61.8%), there is 
a concern about deterioration of the immune population 
in a short or moderate timeframe, with the possibility of 
reactivation of JCV and BKV viruses and subsequent 
clinical deterioration. The long-term consequences of 
co-infection with HIV and polyomavirus should be kept 
under constant surveillance in the study group.
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